Clinical comparative studies of pemetrexed combined with docetaxel in the treatment of advanced non-small-cell lung cancer

Abstract

Objective To investigate the clinical efficacy and toxicity of comparison of the pemetrexed combined with cisplatin and docetaxel of advanced non small cell lung cancer(NSCLC).Methods The clinical data of 102 patients with advanced NSCLC were retrospectively analyzed.Fifty-two patients received pemetrexed combined with cisplatin (Group PC) (pemetrexed 500 mg/m2 intravenous drip in first day,cisplatin 75 mg/m2,intravenous drip in first day to third day,repeated every 21 days); Other 50 patients received the docetaxel combined with cisplatin (Group TP) (docetaxel 75 mg/m2 intravenous drip in first day,cisplatin 75 mg/m2 ntravenous drip in first day to third day,repeated every 21 days).The disease control rate (DCR),progress free survival,median survival time and 1 year survival rate were compared between two groups.Results The efficacy and side effects of all the patients could be evaluated.There was no case with complete remission,43 of partial remission,38 cases of stable and 21 cases of progress.No statistical significance were found between the two groups in DCR (80.8％ (42/52) vs.78.0％ (39/50)),progression-free survival (5.69 vs.4.71 months,P =0.334),median survival time (10.49 vs.10.48 months,P =0.851) and 1 year survival rate (32.0％ vs.24.0％,x2 =1.59,P =0.210).The most common toxicities were arrest of bone marrow and alimentary tract reactions.Pemetrexed could reduce the Leukopenia (P =0.010),the alopecia (P =0.004),the febrile (P =0.024) and tetter (P =0.048); but no significant difference was found in anaemia (P =0.873),thrombocytopenia (P =0.541),nausea and vomiting (P =0.114) and impaired liver function (P =0.403) and impaired renal function (P =0.541).Conclusion Pemetrexed and docetaxel combined with cisplatin for the treatment of advanced NSCLC have similar treatment effects,and the side effect of pemetrexed combined cisplatin is lower. Key words: Advanced non-small-cell lung cancer; Pemetrexed; Docetaxel; Cisplatin